Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Taro Pharmaceutical Ind. (NasdaqNM:TARO) -- Ignore unavailable to you. Want to Upgrade?

To: Smartypts who wrote (13)	7/26/2001 6:07:43 AM
From: Dorine Essey	Respond to of 18

12:01 Nessuah Zannex has reiterated its "Buy" rating for Teva (Nasdaq: TEVA) and raised the target price to $79. Analyst Haim Israel: Teva has one of the strongest management teams in the industry and this, coupled with a winning strategy, drives the company to outperform average growth in the sector. Teva deserves to trade at premium to its peers. . 09:10 Israeli shares on Wall Street (Wed.): Amdocs (DOX) up 11.43% to $42.01; Check Point (CHKP) up 4.22% to $39.47; Mercury (MERQ) up 2.15% to $35.68; Precise Software (PRSE) up 18.74% to $21.99; Taro (TARO) up 1.17% to $95.13; Teva (TEVA) up 5.12% to $68.79. Creo (CREO) down 5.56% to $15.80; Marvell (MRVL) down 5.91% to $23.55; Terayon (TERN) down 11.23% to $4.90.